Prof. Dr. Levente Kovács, Director of Physcon, gave a plenary presentation on the results of the ERC project, which ended in October 2021, at the 11th International IFAC Symposium on Biological and Medical Systems in Geneva. Other presentations from the Physcon team were given by Dr. György Eigner, Dr. András Dániel Drexler and Bence Czakó.
As is well known, in conventional cancer therapies, doses are chosen to be as high as possible, maximising the effect of the drug and minimising the chance of drug resistance. However, this approach increases side effects and costs. Personalisation of treatments can result in lower doses of therapy with the same effect, resulting in lower drug costs and fewer side effects. Physcon has developed tumour models based on ordinary differential equations for several mouse models, including angiogenic inhibitors and cytotoxic drugs. It has also developed regulatory algorithms that focus on problems specific to physiological regulation. In silico tests have demonstrated that Physcon algorithms are also suitable for optimising therapies demonstrated in animal studies. These results were presented by Prof.Dr. Levente Kovács to an international audience.